Akero Therapeutics Inc (AKRO)

Aug 20, 2025

Deutsche Bank AG Has $9.48 Million Position in Akero Therapeutics, Inc. $AKRO - MarketBeat

Aug 20, 2025

Aug 20, 2025

E Fund Management Co. Ltd. Invests $280,000 in Akero Therapeutics, Inc. $AKRO - MarketBeat

Aug 20, 2025

Aug 20, 2025

527,004 Shares in Akero Therapeutics, Inc. $AKRO Bought by Lord Abbett & CO. LLC - MarketBeat

Aug 20, 2025

Aug 19, 2025

Akero Therapeutics COO Jonathan Young sells shares worth $538,060 - MSN

Aug 19, 2025

Aug 19, 2025

Akero Therapeutics (NASDAQ:AKRO) Rating Increased to Hold at Wall Street Zen - MarketBeat

Aug 19, 2025

Aug 19, 2025

Fox Run Management L.L.C. Makes New $642,000 Investment in Akero Therapeutics, Inc. $AKRO - MarketBeat

Aug 19, 2025

Aug 19, 2025

Published on: 2025-08-19 16:09:07 - beatles.ru

Aug 19, 2025

Aug 19, 2025

Andrew Cheng Sells 30,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat

Aug 19, 2025

Aug 19, 2025

Lifesci Capital Has Positive Estimate for AKRO Q3 Earnings - MarketBeat

Aug 19, 2025

Aug 19, 2025

Jonathan Young Sells 12,500 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat

Aug 19, 2025

Aug 18, 2025

Akero Investor Suit Over Liver Drug Trials Permanently Tossed - Law360

Aug 18, 2025

Aug 18, 2025

Latham Wins Dismissal With Prejudice for Pioneering Liver-Disease Drug Company Akero Therapeutics - Latham & Watkins LLP

Aug 18, 2025

Aug 18, 2025

Akero Defeats Investor Lawsuit Over Liver Drug Trial’s Design - Bloomberg Law News

Aug 18, 2025

Aug 18, 2025

Analysts Divided on Akero Therapeutics and Kodiak Sciences: AKRO and KOD Ratings Revealed - AInvest

Aug 18, 2025

Aug 18, 2025

Informed Momentum Co LLC Acquires New Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Aug 18, 2025

Aug 16, 2025

20,253 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by Aigen Investment Management LP - MarketBeat

Aug 16, 2025

Aug 16, 2025

Akero Therapeutics (NASDAQ:AKRO) Shares Down 5.8%Here's Why - MarketBeat

Aug 16, 2025

Aug 16, 2025

Akero Therapeutics Inc. Shows Risk Reward Favoring Upside2025 Volume Leaders & AI Enhanced Trading Alerts - kangso.co.kr

Aug 16, 2025

Aug 15, 2025

Akero Therapeutics shares fall 3.81% after-hours following publication of Phase 2b HARMONY trial results in The Lancet. - AInvest

Aug 15, 2025

Aug 15, 2025

Reversal Confirmed Akero Therapeutics Inc. Stock Rallies Above MAJuly 2025 Institutional & High Conviction Buy Zone Alerts - sundaytimes.kr

Aug 15, 2025

Aug 15, 2025

Akero Therapeutics shares fall 2.85% intraday as investors take profits and insiders sell stock. - AInvest

Aug 15, 2025

Aug 15, 2025

Published on: 2025-08-15 12:12:33 - metal.it

Aug 15, 2025

Aug 14, 2025

Akero Therapeutics’ efruxifermin shows efficacy in Phase 2b MASH, fibrosis trial - TipRanks

Aug 14, 2025

Aug 14, 2025

EFX's 96-Week HARMONY Trial: A Paradigm Shift in MASH Treatment and a High-Conviction Buy Case for AKRO - AInvest

Aug 14, 2025

Aug 14, 2025

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH - GlobeNewswire

Aug 14, 2025

Aug 14, 2025

Nearly Half of Patients See Liver Fibrosis Improvement: Akero's EFX Drug Shows Promise in 96-Week MASH Study - Stock Titan

Aug 14, 2025

Aug 14, 2025

Akero Therapeutics: Contrarian Opportunity Amid FDA Approval and Insider Selling - AInvest

Aug 14, 2025

Aug 14, 2025

Reversing Akero Therapeutics Contrarian Buy Rating to Contrarian Sell Rating - AInvest

Aug 14, 2025

Aug 14, 2025

Akero Therapeutics: Why I'm Reversing My Contrarian Buy Rating To A Contrarian Sell Rating - Seeking Alpha

Aug 14, 2025

Aug 14, 2025

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus - Zacks Investment Research

Aug 14, 2025

Aug 14, 2025

Insider Selling and Market Confidence at Akero Therapeutics: A Balancing Act of Strategy and Optimism - AInvest

Aug 14, 2025

Aug 14, 2025

Akero Therapeutics Insider Sold Shares Worth $1,457,596, According to a Recent SEC Filing - MarketScreener

Aug 14, 2025

Aug 14, 2025

Akero Therapeutics Insider Sold Shares Worth $597,326, According to a Recent SEC Filing - MarketScreener

Aug 14, 2025

Aug 13, 2025

Akero Therapeutics COO Young sells $597k in shares By Investing.com - Investing.com Australia

Aug 13, 2025

Aug 13, 2025

Akero Therapeutics COO Young sells $597k in shares - Investing.com

Aug 13, 2025

Aug 13, 2025

Akero Therapeutics CEO Cheng sells $1.46 million in stock By Investing.com - Investing.com Canada

Aug 13, 2025

Aug 13, 2025

Akero Therapeutics CEO Cheng sells $1.46 million in stock - Investing.com India

Aug 13, 2025

Aug 13, 2025

Akero Therapeutics Executives Sell Shares - TradingView

Aug 13, 2025

Aug 13, 2025

Akero Therapeutics (NASDAQ:AKRO) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat

Aug 13, 2025

Aug 13, 2025

Sentiment Turns Positive on Akero Therapeutics Inc. — Reversal AheadTrade Performance Summary & Weekly Momentum Picks - metal.it

Aug 13, 2025

Aug 12, 2025

Vivo Capital LLC Invests $8.14 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Aug 12, 2025

Aug 12, 2025

Akero therapeutics director Henderson sells $142k in shares By Investing.com - Investing.com Nigeria

Aug 12, 2025